The Mounjaro “golden dose” trend has taken over weight loss treatment communities on TikTok, Reddit, and Mounjaro user groups, with people sharing tips and videos on how to squeeze a fifth injection out of a weight loss injection pen that was only ever designed to deliver four.
Given the cost of Mounjaro in the UK, the appeal is understandable. But there is a difference between leftover medication and a usable dose, and that distinction matters more than most people realise.
Each Mounjaro KwikPen is designed to deliver exactly 4 doses. The pen is pre-filled and engineered to inject a precise amount of tirzepatide each time it is used.
After the fourth injection, some liquid does remain in the pen. This is not a bonus dose.
It’s known as overfill: the extra liquid built into the device to prime a Mounjaro pen before each injection, make sure the mechanics work correctly, and ensure all four doses are delivered accurately. It serves a similar purpose to the residual fluid that keeps a pump functioning, rather than being usable product in reserve.
The term “golden dose” was coined by online communities to describe the liquid left in a Mounjaro KwikPen after the fourth injection. The trend spread through weight loss forums, TikTok, and Reddit, driven largely by the cost of this weight loss medication and ongoing supply pressures. Some users began extracting the leftover liquid using needles and syringes, and sharing their methods with others.
The idea of usable medication sitting in a spent pen is understandably appealing. But the residual liquid is not a measured dose, and there are risks if you decide to use it as part of your treatment plan.
The core problem with taking an extra dose from your pen is that the Mounjaro fifth dose is not a prescribed dose. Using it means self-administering an unknown quantity of tirzepatide outside of any clinical guidance.
The KwikPen cannot measure or guarantee the amount of medication left after the fourth injection. The amount of liquid varies between pens, and the device is not designed to deliver it in a controlled way. There is simply no way to know how much Mounjaro you’re getting from the residual liquid, which means you cannot be certain you are receiving an accurate dose.
The KwikPen needle is designed for single-session use. Attempting to extract residual medication using a separate syringe or needle introduces a genuine risk of contamination and infection at the injection site.
Your prescriber has prescribed a specific dose on a specific schedule. The golden dose sits entirely outside that. Your prescriber has no visibility of it, cannot account for it, and cannot safely manage your treatment around it.
Tirzepatide is a GLP-1 medication, and dose escalation is carefully and deliberately managed. The titration schedule exists because introducing too much of the drug too quickly causes significant gastrointestinal side effects and tolerability problems. An uncontrolled and unmeasured dose disrupts that carefully managed process.
The manufacturer of Mounjaro, Eli Lilly, has not approved any use of residual medication from the KwikPen, and UK prescribing guidance doesn’t support it.
The overfill in the KwikPen is an engineering requirement, not a hidden extra dose. The pen is designed to need a small amount of residual liquid to function correctly and to make sure all four prescribed doses are delivered in full. It is not surplus medication sitting unused.
Uncontrolled micro-dosing is not inherently safer than a full dose. You have no way of knowing how much tirzepatide is in the residual liquid or how much you are actually injecting. Small and unpredictable amounts of the drug can still cause side effects and can interfere with your prescribed treatment plan.
The clinical outcomes seen in the SURMOUNT trials were built on consistent, prescribed dosing. Introducing an additional, unmeasured dose disrupts the regularity that underpins those results. Inconsistent dosing can affect tolerability, side effects, and ultimately how well the treatment works for you.
Social media shows you the people who report no problems. It doesn’t show you the people who experienced adverse effects, sought medical attention, or simply stopped posting. Survivorship bias is a significant issue in online health communities, and adverse events are consistently underreported.
The presence of liquid doesn’t make it a dose. The KwikPen is not calibrated to deliver a fifth injection, and the remaining liquid cannot be extracted or administered with any meaningful accuracy using the device as intended.
Mounjaro is injected once a week, and the dose starts low and increases gradually over time. The standard schedule ranges from 2.5mg to a maximum of 15mg, increasing by 2.5 mg every 4 weeks: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg. The final step, 15mg, is considered the maintenance dose.
Each pen contains four weekly doses, so one pen lasts four weeks.
Not everyone will reach the highest dose. Your prescriber will decide when, or whether, to increase your current dose based on how you are getting on with the treatment.
Tirzepatide affects receptors in the gut and brain, and increasing your dose too quickly causes side effects like nausea, vomiting, and stomach pain. A gradual increase gives your body time to adjust, making the treatment much easier to tolerate.
If you miss a dose, you can still take it within four days of your usual injection day. After that, skip it and wait until your next scheduled dose. Never take two doses at once to catch up.
Any changes to how you use Mounjaro should be made with your prescriber, not independently.
In March 2026, Eli Lilly announced a modification to the Mounjaro KwikPen that reduces the amount of liquid left after the fourth dose.
The pen itself stays the same size. What changes is the volume of the solution inside it. The modified pen will still contain enough liquid to prime before each injection and deliver four complete doses, but not enough left over to attempt a fifth.
The updated pen has already been introduced in other countries, including the US. It has been approved in the UK, with Eli Lilly confirming it will be rolled out from April 2026.
The reaction in online communities has been largely negative, with many users frustrated at losing what they saw as a cost-saving measure. Some have said they will still attempt to extract residual liquid from the new pen. This remains inadvisable, regardless of how little is left.
There has also been a rise in unofficial “conversion kits” being sold online, marketed as tools to help extract the golden dose. These are not sterile medical devices; they are not regulated, and using them introduces significant infection risk on top of the dosing accuracy problems already associated with the golden dose.
If the cost of Mounjaro is a genuine concern, the answer is not to stretch your pen. It is to speak to someone who can actually help.
Click2Pharmacy is a regulated UK online pharmacy providing Mounjaro under full clinical oversight. Every patient is seen by a GMC-registered prescriber and a qualified pharmacist, receives genuine manufacturer-supplied medication, and has access to ongoing clinical support throughout their treatment. You will always know exactly what dose you are taking and when.
Start your Mounjaro consultation with Click2Pharmacy today.
Get 10% Off Your First Order
Sign up to receive special offers via email and get 10% off your first order*
By opting in to marketing, you agree to our terms & conditions and privacy policy.
